Muscular Atrophy, Spinal
Neurology·MeSH: Muscular Atrophy, Spinal
Prevalence
5.0 / 100K
4 drugs in development·2 companies·8 clinical trials
Drug Pipeline by Phase
Phase 3(2)
Phase 2(1)
| Drug | Company |
|---|---|
| Risdiplam | PTC THERAPEUTICS, INC. (PTCT) |
Phase 1(1)
| Drug | Company |
|---|---|
| Nusinersen | BIOGEN INC. (BIIB) |
Compare drugs
Frequently asked questions
How many drugs are in development for Muscular Atrophy, Spinal?
BioSniper tracks 4 drugs in development for Muscular Atrophy, Spinal across 2 companies.
How many clinical trials target Muscular Atrophy, Spinal?
There are 8 clinical trials targeting Muscular Atrophy, Spinal tracked by BioSniper.
What is the prevalence of Muscular Atrophy, Spinal?
The estimated prevalence of Muscular Atrophy, Spinal is approximately 5.0 per 100,000 population.
Deep-dive into Muscular Atrophy, Spinal
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis